Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.

Trial Details

NCT ID
NCT07151040
Phase
PHASE1 / PHASE2
Sponsor
One-carbon Therapeutics AB
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • TH9619
Locations (sample)
  • Villejuif, France|48.7939,2.35992
  • Barcelona, Spain|41.38879,2.15899
  • Madrid, Spain|40.4165,-3.70256
  • Newcastle upon Tyne, United Kingdom|54.97328,-1.61396

Key Eligibility Criteria

  • Must have given written informed consent
  • Histopathologically confirmed advanced cancer (colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer and gastric cancer…
  • Prior treatment with at least one line of cytotoxic systemic therapy for metastatic/unresectable cancer
  • Adult patients (≥18 years of age)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →